Sera Prognostics, Inc., (SERA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SERA Stock Summary
- SERA PROGNOSTICS INC's stock had its IPO on July 15, 2021, making it an older stock than merely 3.61% of US equities in our set.
- With a price/sales ratio of 177.43, SERA PROGNOSTICS INC has a higher such ratio than 98.35% of stocks in our set.
- With a year-over-year growth in debt of 732.41%, SERA PROGNOSTICS INC's debt growth rate surpasses 97.28% of about US stocks.
- If you're looking for stocks that are quantitatively similar to SERA PROGNOSTICS INC, a group of peers worth examining would be BASE, MASS, LVOX, VORB, and RNLX.
- To dig deeper into the stock's financial statements, go to SERA's page on browse-edgar?action=getcompany&CIK=0001534969.
SERA Valuation Summary
- SERA's price/sales ratio is 178.6; this is 3620.83% higher than that of the median Healthcare stock.
- SERA's price/sales ratio has moved down 14345.4 over the prior 17 months.
Below are key valuation metrics over time for SERA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SERA | 2022-11-25 | 178.6 | 0.4 | -0.9 | -0.1 |
| SERA | 2022-11-23 | 178.6 | 0.4 | -0.9 | -0.1 |
| SERA | 2022-11-22 | 173.4 | 0.4 | -0.8 | 0.0 |
| SERA | 2022-11-21 | 174.7 | 0.4 | -0.9 | -0.1 |
| SERA | 2022-11-18 | 183.0 | 0.4 | -0.9 | -0.1 |
| SERA | 2022-11-17 | 173.4 | 0.4 | -0.8 | 0.0 |
SERA Price Target
For more insight on analysts targets of SERA, see our SERA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $18.00 | Average Broker Recommendation | 1.17 (Strong Buy) |
SERA Stock Price Chart Interactive Chart >
SERA Price/Volume Stats
| Current price | $1.32 | 52-week high | $10.66 |
| Prev. close | $1.32 | 52-week low | $1.15 |
| Day low | $1.23 | Volume | 19,700 |
| Day high | $1.32 | Avg. volume | 70,595 |
| 50-day MA | $1.49 | Dividend yield | N/A |
| 200-day MA | $2.25 | Market Cap | 40.94M |
Sera Prognostics, Inc., (SERA) Company Bio
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest SERA News From Around the Web
Below are the latest news stories about SERA PROGNOSTICS INC that investors may wish to consider to help them evaluate SERA as an investment opportunity.
FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICSSera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Fors Marsh, a company dedicated to solving complex challenges through market research, are collaborating to provide Sera's PreTRM® Test to employees at Fors Marsh as part of their maternity benefits, effective January 1, 2023. |
SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONSSera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT (Analyses aCross Congruent studies ReDucing Adverse pregNancy ouTcomes). The newly published study reports: |
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue EstimatesSera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 12.50% and 2.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTSSera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter ended September 30, 2022. |
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern |
SERA Price Returns
| 1-mo | 1.54% |
| 3-mo | -34.00% |
| 6-mo | 1.54% |
| 1-year | -86.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -80.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...